Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

1.

Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist.

Gole P, Madke B, Khopkar U, Kumar P, Noronha V, Yadav M.

Indian Dermatol Online J. 2014 Jan;5(1):89-91. doi: 10.4103/2229-5178.126049. No abstract available.

PMID:
24616870
[PubMed]
Free PMC Article
2.

Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.

Sulkes A.

Isr Med Assoc J. 2010 Oct;12(10):628-32. Review.

PMID:
21090521
[PubMed - indexed for MEDLINE]
Free Article
3.

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.

Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H.

Eur Urol. 2008 Dec;54(6):1373-8. doi: 10.1016/j.eururo.2008.07.051. Epub 2008 Aug 8.

PMID:
18692304
[PubMed - indexed for MEDLINE]
4.

5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.

Miyake M, Anai S, Fujimoto K, Ohnishi S, Kuwada M, Nakai Y, Inoue T, Tomioka A, Tanaka N, Hirao Y.

Oncol Lett. 2012 Jun;3(6):1195-1202. Epub 2012 Mar 29.

PMID:
22783417
[PubMed]
Free PMC Article
5.

Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.

Huynh H, Choo SP, Toh HC, Tai WM, Chung AY, Chow PK, Ong R, Soo KC.

Curr Cancer Drug Targets. 2011 Oct;11(8):944-53.

PMID:
21834756
[PubMed - indexed for MEDLINE]
6.

Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.

Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, Dahl GV, Rubnitz J, Baker SD.

Mol Cancer Ther. 2008 May;7(5):1110-20. doi: 10.1158/1535-7163.MCT-07-2218.

PMID:
18483300
[PubMed - indexed for MEDLINE]
Free Article
7.

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.

Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.

J Urol. 2008 Jan;179(1):81-6; discussion 86. Epub 2007 Nov 12.

PMID:
17997441
[PubMed - indexed for MEDLINE]
8.

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.

Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI.

Eur Urol. 2008 May;53(5):917-30. Epub 2007 Nov 26. Review.

PMID:
18054825
[PubMed - indexed for MEDLINE]
9.

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.

Buchler T, Klapka R, Melichar B, Brabec P, Dusek L, Vyzula R, Abrahamova J.

Ann Oncol. 2012 Feb;23(2):395-401. doi: 10.1093/annonc/mdr065. Epub 2011 May 2.

PMID:
21536664
[PubMed - indexed for MEDLINE]
Free Article
10.

Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.

Sugiyama M, Fujita K, Murayama N, Akiyama Y, Yamazaki H, Sasaki Y.

Drug Metab Dispos. 2011 May;39(5):757-62. doi: 10.1124/dmd.110.037853. Epub 2011 Jan 25.

PMID:
21266595
[PubMed - indexed for MEDLINE]
Free Article
11.

Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.

Martin B, Edeline J, Patard JJ, Oger E, Jouan F, Boulanger G, Zerrouki S, Vigneau C, Rioux-Leclercq N.

J Cancer Res Clin Oncol. 2012 Jun;138(6):907-16. doi: 10.1007/s00432-012-1162-x. Epub 2012 Feb 10.

PMID:
22322364
[PubMed - indexed for MEDLINE]
12.

Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.

Wong MK, Jarkowski A.

Pharmacotherapy. 2009 Apr;29(4):473-8. doi: 10.1592/phco.29.4.473. Review.

PMID:
19323623
[PubMed - indexed for MEDLINE]
13.

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.

Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P.

Blood. 2008 Jun 15;111(12):5610-20. doi: 10.1182/blood-2007-02-075945. Epub 2008 Feb 29.

PMID:
18310500
[PubMed - indexed for MEDLINE]
Free Article
14.

A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.

Paglino C, Procopio G, Sabbatini R, Bellmunt J, Schmidinger M, Bearz A, Bamias A, Melichar B, Imarisio I, Tinelli C, Porta C.

Anticancer Res. 2013 Nov;33(11):4999-5004.

PMID:
24222142
[PubMed - indexed for MEDLINE]
15.

Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E.

J Clin Oncol. 2013 Nov 10;31(32):4067-75. doi: 10.1200/JCO.2012.45.8372. Epub 2013 Sep 30.

PMID:
24081937
[PubMed - indexed for MEDLINE]
16.

Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.

Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

Chemotherapy. 2012;58(6):468-74. doi: 10.1159/000346484. Epub 2013 Mar 20.

PMID:
23548259
[PubMed - indexed for MEDLINE]
17.

Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.

Ambring A, Björholt I, Lesén E, Stierner U, Odén A.

Med Oncol. 2013 Mar;30(1):331. doi: 10.1007/s12032-012-0331-8. Epub 2012 Dec 18.

PMID:
23254966
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.

Feldt S, Schüssel K, Quinzler R, Franzmann A, Czeche S, Ludwig WD, Schulz M.

Eur J Cancer. 2012 May;48(7):974-81. doi: 10.1016/j.ejca.2012.01.036. Epub 2012 Feb 28.

PMID:
22382202
[PubMed - indexed for MEDLINE]
19.

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.

Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E.

BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23.

PMID:
21599821
[PubMed - indexed for MEDLINE]
20.

Sequential sorafenib and sunitinib for renal cell carcinoma.

Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B.

J Urol. 2009 Jul;182(1):29-34; discussion 34. doi: 10.1016/j.juro.2009.02.119. Epub 2009 May 17.

PMID:
19447417
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk